
We are pleased to announce the next CQM Seminar titled "Bench-to-bedside translation of nanoparticles in oncology: Dendrimers case studies, reality or utopia?" with Professor Serge Mignani, senior researcher at CQM and at Centre d’Études et de Recherche sur le Médicament de Normandie & Argobio Studio, Paris (France). This seminar will take place on the 03rd of December 2025 at the conference room 0.57, Campus of Penteada, University of Madeira, starting at 15:00.
Space is limited, so please be sure to complete your registration as soon as possible.
Abstract:
Cancer is the most dangerous disease in the world in terms of mortality and lack of effective treatment. Research on cancer treatment is still active and of great social importance. Since 1930, chemotherapeutics have been used to treat cancer. However, such conventional therapies are associated with pain, side effects, and a lack of targeting. Nanomedicines are an emerging alternative due to their targeting, bioavailability, and low toxicity. Among the numerous nanomedicine formulations, dendrimers have emerged as original, efficient, carefully assembled, hyperbranched, polymeric nanoparticles based on synthetic monomers. Nanotechnology has made a significant impact on the delivery of drugs, as well as through their development as drugs themselves. Dendrimers are used either as nanocarriers of drugs or as drugs themselves. The purpose of this presentation is to analyze the different strategies involved in the development, application, and impact of dendrimers as nanodrugs as well as nanocarriers. We will analyze the clinical translation process of dendrimers and the main challenges. Also, we will examine a selection of nanoparticles that use multifunctional elements and demonstrate clinical multifunctionality, and we will extend these principles to applications in dendrimer nanomedicine design. Finally, for practical consideration, the concepts of vertical and diagonal translation will be discussed as potential strategies to facilitate dendrimer development.
| Registration until 02nd of December 2025. | |
| Registration form Limited seats available |

| Registration until 02nd of December 2025. | |
| Registration form Limited seats available |

CQM Welcomes a New Assistant Researcher
The Madeira Chemistry Research Centre (CQM) is pleased to announce that, within the aim of the 7th edition of the Individual Scientific Employment Stimulus Call by the Foundation for Science and Technology (FCT), another Assistant Researcher contract has been approved, with CQM as the host institution.
Oriana Marques was selected in this highly competitive call, in which only 14.4% of applications were successful, highlighting the scientific excellence and high potential of the approved proposal.
After eight years at Heidelberg University and the European Molecular Biology Laboratory (EMBL) in Germany, where she established herself as a specialist in iron metabolism and inflammatory diseases, Dr. Oriana Marques is now returning to Portugal to continue her research at CQM.
The three-year contract aligns with CQM’s strategic priorities for the coming years and will enable the development of innovative nanoparticle-based therapies for Anemia of Inflammation—a condition affecting millions of patients worldwide with chronic inflammatory diseases.
This project combines CQM’s established expertise in developing nanomaterials for biomedical applications with Dr. Oriana Marques’ specialized knowledge in iron biology and immune system regulation. The goal is to create “smart” nanoparticles capable of selectively targeting immune cells, restoring appropriate iron levels in patients, and paving the way for new therapeutic approaches to anemia associated with autoimmune diseases, cancer, and other chronic inflammatory conditions.
Following the approval of two other Assistant Researcher positions in previous calls, this third FCT-funded contract represents further recognition and strengthens CQM’s position in the international landscape of biomedical research and nanomedicine, by integrating into its team a highly qualified researcher with solid scientific experience and established collaborations with leading international institutions.

CQM joins INL in European platform for the development of new semiconductor chips.
The Madeira Chemistry Research Centre (CQM) has partnered with the INL – International Iberian Nanotechnology Laboratory to join the INFRACHIP, an European research platform dedicated to the sustainable development of the next generation of semiconductor chips.
Through INFRACHIP, researchers can access cutting-edge technologies installed across various parts of Europe free of charge.
CQM is participating in this initiative with the project "Heteroatom-doped and co-doped CDs: characterization", which was recently selected by a European panel to be part of the platform. This partnership will allow CQM researchers involved in the project to access highly specialized knowledge and advanced technologies in electron and X-ray microscopy available at INL. These are essential tools for the structural and morphological characterization of carbon nanomaterials, particularly carbon dots.
These nanomaterials, composed mainly of carbon but which may also contain oxygen and/or nitrogen atoms, exhibit unique optical properties and hold great potential for biomedical applications, especially in bioimaging. At CQM, carbon dots are being developed as part of the PhD project of junior researcher Ivo Martins, titled Fluorescent Carbon dot-cored dendritic polymers as novel cancer theranostics nanoarchitectures, funded by the Foundation for Science and Technology (Ref. 2021.05990.BD) and supervised by Professor João Rodrigues, Full Professor in the Department of Chemistry at the University of Madeira and senior member of CQM.
The first results of this collaboration have already enabled the observation and identification of new carbon nanostructures, with further structural and biochemical characterization studies currently underway. These efforts aim to pave the way for new applications of these materials not only in the field of next-generation chips and bioimaging but also in catalytic processes of high scientific and technological interest.